Study of SHR-A1912 plus chemotherapy for DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (a type of blood cancer).
- You have already had at least one round of treatment for your lymphoma.
- You have at least one tumor that can be measured on a scan (at least 1.5 cm in one direction).
- You are between 18 and 79 years old.
- You are willing to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination therapy for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to see if adding SHR-A1912 to other treatments can help shrink tumors.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a new drug, SHR2554, for people with follicular lymphoma that has returned or not responded to prior treatments. It aims to see if the drug can shrink tumors and slow the cancer's growth.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.